mAb – Ingenious Biomolecules for a Wide Range of Applications
From Abciximab to Zolbetuximab – the list of therapeutic monoclonal antibodies (mAbs) is long and constantly growing. The need for reliable, scalable manufacturing systems is growing along with it. ZETA has been a leader in the development of technical solutions for liquid aseptic production systems for years. A track record of successfully completed projects underlines ZETA’s distinct advantage in the design of customized systems for mAb production.
Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities. ZETA supports its customers along the entire drug development and manufacturing pathway with sophisticated solutions from laboratory to industrial production scale. Through its Smart Engineering Services, ZETA creates digital twins of process plants and has thus established itself as a market leader for digital solutions in the pharmaceutical and biotech industry.
ZETA is also actively taking steps towards a more sustainable future for the industry as a whole: through ZETA's decarbonization strategies, emissions are specifically reduced during the biopharmaceutical manufacturing process.
